Red Light Holland

Name

Red Light Holland

Legal name

Red Light Holland

Website

https://redlight.co

Company type

Public

Founded year

1982

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Psychedelic Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Herbal & Botanical Supplements (CRADAGAD)

akta.pro secondary industry

Hemp & CBD Product Wholesale Distribution (CRAOAIAG)

Keywords

• Psilocybin truffle production
• Natural psychedelic drug development
• Mushroom home grow kits
• Clinical research drug supply
• Smart shop distribution

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Psilocybin Truffle Sales: Production and sale of premium psilocybin truffles in the Netherlands' legal adult-use market through Red Light Rec brand. Revenue generated from direct consumer sales via iMicrodose.nl and distribution through smart shop retail partners.
2. Mushroom Home Grow Kit Sales: Sale of grow-at-home mushroom kits through wholly owned subsidiary Happy Caps. Products distributed through major retail channels including Costco Canada (82+ stores), Safeway/Albertsons (123 stores), Urban Outfitters, and Longo's. B2B and DTC sales models.
3. Pharmaceutical Drug Development: Revenue generation through licensing and supply agreements for PEX010 botanical psilocybin drug candidate to academic institutions and clinical research sites. The company supplies drug candidate to 80+ studies globally and pursues drug development toward commercialization.
4. Wholesale Distribution: SR Wholesale B.V. generates revenue through distribution and export of truffles, CBD products, cannabis seeds, Smartshop items, Headshop products, and Growshop goods across the Netherlands and EU markets.

Pricing tiers

Go-to-market motion3 records

Distribution channels7 records

Marketing channels6 records

Core offering

Red Light Holland produces and distributes premium psilocybin truffles in the Netherlands legal adult-use market through its Red Light Rec brand and iMicrodose kits, and sells mushroom home grow kits through subsidiaries such as Happy Caps via major retail channels. Following its April 2026 acquisition of Filament Health, the company also develops and supplies pharmaceutical-grade natural psilocybin drug candidates, principally PEX010, to academic and clinical research institutions globally, supported by GMP-compliant manufacturing and 70+ patents.

Differentiator

Problem solved

Functional benefit

Brands

• SR Wholesale: Dutch company specialized in selection, distribution and export of Truffles, CBD products, cannabis seeds, Smartshop items, Headshop products, Growshop goods and Cannabis Bake House products
• Radix Motion
• Happy Caps
• iMicrodose
• Wisdom Truffle
• FarmCare
• MisterCap
• MiniChamp BV

Products and services

• PEX010 Botanical Psilocybin Drug Candidate Pharmaceutical-grade standardized natural psilocybin drug candidate produced by wholly owned subsidiary Filament Health, intended for academic and clinical research in psychedelic-assisted therapies and supplied under GMP-compliant manufacturing.
• iMicrodose Microdosing Kits Pre-packaged psilocybin truffle microdosing kits sold directly to adult consumers in the Netherlands legal adult-use market.
• Red Light Rec Premium Magic Truffles Premium psilocybin truffles supplied by Red Light Rec to smart shops and through iMicrodose.nl for the Netherlands legal adult-use market.
• Happy Caps Mushroom Home Grow Kits Urban gourmet grow-your-own mushroom kits, including the 2kg Mega Block, sold direct-to-consumer via HappyCaps.ca and through retail partners including Costco Canada and Safeway/Albertsons in North America.
• Wisdom Truffle Augmented reality companion figurine promoting positivity and responsible technology use, integrated with Red Light Holland's AR platform.
• Mistercap Mushroom Home Grow Kits

Quantifiable outcome

• 69% of cancer patients fell below clinical thresholds for anxiety and depression after second psilocybin treatment session with improvements sustained for 24 weeks
• +2 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

14 partnerships are on record, tiered core and minor.

• Jaguar HealthcoreStrategic or Co-development Partner · 18 June 2026Magdalena Biosciences joint venture partnership with Jaguar Health developing coca leaf extract as prescription drug candidate for post-GLP-1 weight loss management. Jaguar disclosed Q1 2026 revenue of $20.2 million representing 816% growth year-over-year. Red Light holds interest through Filament Health acquisition.
• GHU Paris Psychiatrie & NeurosciencescoreStrategic or Co-development Partner · 8 June 2026Filament Health signed agreement to supply PEX010 botanical psilocybin drug candidate for KETAPSYCHECOG study, a randomized double-blinded cross-over trial comparing behavioral and neural effects of psilocybin and ketamine in healthy volunteers. Agreement adds France to Filament's expanding international clinical research footprint.
• UCSF (University of California San Francisco)coreStrategic or Co-development Partner · 4 June 2026Filament Health signed agreement to supply PEX010 botanical psilocybin drug candidate to UCSF for double-blind randomized clinical trial investigating psychedelics in healthy older adults with low well-being, examining biomarkers for preclinical Alzheimer's disease using EEG and MRI imaging. Part of Dr. Robin Carhart-Harris's Global Psychedelic Study.
• Allu TherapeuticscoreChannel Partner/ Reseller/ Distributor · 25 May 2026Expanded partnership with Allu Therapeutics in New Zealand by adding Filament Health as supplying affiliate under existing supply agreement. Introduced first GMP-compliant standardized microdose format of PEX010 botanical psilocybin drug candidate. Supports New Zealand's regulatory framework permitting authorized psychiatrists to prescribe psilocybin to treatment-resistant patients.
• University of British ColumbiacoreStrategic or Co-development Partner · 14 May 2026Filament Health shipped PEX010 botanical psilocybin drug candidate to UBC for clinical studies in palliative care, bipolar II depression, and healthy adult mechanism research. UBC study addresses understudied bipolar disorder population largely excluded from prior psychedelic clinical trials.
• Irvine LabscoreTechnology or Integration · 13 May 2026FDA-compliant, DEA-registered partner receiving psilocybin shipments from Netherlands facility under US Controlled Substances import permits. Second 5kg shipment received in November 2025. Supports R&D activities and manufacturing of microdosing psilocybin capsules.
• Filament Health Corp.coreStrategic or Co-development Partner · 29 April 2026Red Light Holland completed acquisition of Filament Health effective April 29, 2026, through statutory plan of arrangement under British Columbia law. Filament became a wholly owned subsidiary, adding GMP-certified manufacturing, 76 issued patents, Health Canada Dealer's License, and PEX010 botanical psilocybin drug candidate. Exchange ratio of 0.36634769 shares per Filament share, with former Filament shareholders holding approximately 30% of combined company.
• University of CalgarycoreStrategic or Co-development Partner · 24 April 2026Repeat shipments of PEX010 botanical psilocybin drug candidate to University of Calgary supporting multiple clinical trials including alcohol use disorder, post-concussion symptoms, and treatment-resistant depression. Growing demand for pharmaceutical-grade naturally-derived psilocybin.
• Arizona State UniversityminorStrategic or Co-development Partner · 23 March 2026Partnership with Arizona State University to support groundbreaking Psychedelic Genome Project (PGP) research study. Collaboration contributes to understanding of psychedelic compounds and genetics.
• Drug Science ConsortiumminorStrategic or Co-development Partner · 23 March 2026Partnership with Drug Science to analyze iMicroapp data and promote responsible regulations for psilocybin microdosing. CTIO presented research findings to Drug Science Consortium.
• Kala Bio (KALA)coreTechnology or Integration · 18 March 2026Red Light Holland engaged Kala Bio's Researgency.ai on-premises AI infrastructure platform to support clinical development of PEX010 botanical psilocybin drug candidate. The AI platform assists in planning, protocol optimization, and scenario modeling for regulated clinical trials. KALA positioned this as first deployment client targeting the $180+ billion AI-in-healthcare market.
• Younet AIcoreTechnology or Integration · 4 March 2026Kala Bio signed Platform Development and Exclusive License Agreement with Younet AI (2624465 Ontario Inc.) to build and deploy Researgency.ai on-premises AI infrastructure platform for biotechnology industry, enabling biotech companies to leverage AI without surrendering control of proprietary biological data.
• Trailbridge Mushroom FarmsminorChannel Partner/ Reseller/ Distributor · 27 September 2025Happy Caps partnered with Trailbridge Mushroom Farms to expand mushroom home grow kit production in the USA, increasing manufacturing capacity for U.S. retail distribution.
• Happy Caps Mushroom FarmcoreStrategic or Co-development Partner · 10 June 2021Red Light Holland completed 80% acquisition of Happy Caps Mushroom Farm in Nova Scotia for $450,000 (shares and cash) to expand market reach and product offerings in grow-at-home mushroom kits with potential future expansion into Europe and functional mushroom products.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Canopy Growth Corporation: Large-scale Canadian cannabis company founded by Bruce Linton (now Red Light's Advisory Board Chairman). Analog for what a vertically integrated natural product platform looks like at scale, and a model for how capital cycles can play out in regulated botanicals.

Direct peers

• Filament Health: Natural psilocybin drug developer and now a wholly owned subsidiary of Red Light Holland. Pre-acquisition Filament was the closest direct comparable, supplying PEX010 to academic clinical trials and operating a GMP facility — essentially the pharmaceutical arm that now defines Red Light's pharma business.
• Compass Pathways: Clinical-stage psychedelic medicine company developing synthetic psilocybin therapy (COMP360) for treatment-resistant depression. Direct peer competing for the same clinical and regulatory beachhead with a different (synthetic) formulation strategy.
• Mind Medicine (MindMed): Psychedelic medicine biotech developing LSD and psilocybin-based therapies for mental health and addiction. Operates in the same pharmaceutical psychedelic category with a publicly listed clinical pipeline.
• ATAI Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic compounds for mental health indications. Competes in the same drug development space with a broader compound portfolio approach.
• Cybin Inc. Clinical-stage psychedelic therapeutics company developing psilocybin-based treatments for depression and addiction. Publicly listed peer with overlapping clinical indications and competing supply partnerships.
• GH Research: Clinical-stage biopharmaceutical company developing mebufotenin and other psychedelic compounds for treatment-resistant depression. Comparable psychedelic drug developer focused on pharmaceutical pathways.

Emerging players

• Numinus Wellness: Mental health company operating psychedelic-assisted therapy clinics and psilocybin research. Overlaps with Red Light's clinical footprint via compassionate access and clinic networks.
• Field Trip Health: Operator of ketamine-assisted psychotherapy clinics exploring psilocybin protocols. Adjacent clinical delivery model sharing mental health indications with PEX010's research programs.
• Jaguar Health: Commercial-stage plant-derived pharmaceutical company and joint venture partner with Red Light's Magdalena Biosciences for coca leaf extract development. Comparable botanical drug development approach and target indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks3 records

Key highlights6 records

Customer concentration

• Instagraminstagram.com/redlightholland
• Xx.com/redlighttrip
• Facebookfacebook.com/redlightholland
• LinkedInlinkedin.com/company/red-light-holland

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries8 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Red Light Holland